Macrophage migration inhibitory factor in clinical kidney disease

Frontiers in Immunology

Volumn 7, Issue JAN, 2016, Pages

  Bruchfeld, Annette ^a   Wendt, Mårten ^a   Miller, Edmund J ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

ADPKD; AKI; CKD; Diabetic nephropathy; Glomerulonephritis; MIF; MIF gene polymorphism; Vasculitis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; C REACTIVE PROTEIN; CD74 ANTIGEN; CREATININE; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; THYROXINE; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN I; TUMOR NECROSIS FACTOR;

ALBUMINURIA; ANCA ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASE; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PYELONEPHRITIS; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84958161401     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00008     Document Type: Short Survey

References (76)

1. David JR. Delayed hypersensitivity in vitro: its mediation by cellfree substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 56:72-7. doi: 10.1073/pnas.56.1.72
2. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (1966) 153:80-2. doi:10.1126/science.153.3731.80
3. Bloom BR, Shevach E. Requirement for T cells in the production of migration inhibitory factor. J Exp Med (1975) 142:1306-11. doi:10.1084/jem.142.5.1306
4. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 3(10):791-800. doi:10.1038/nri1200
5. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine (1998) 10(3):199-205. doi:10.1006/cyto.1997.0276
6. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 13(5):587-96. doi:10.1038/nm1567
7. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 280:36541-4. doi:10.1074/jbc. C500243200
8. Suzuki M, Sugimoto H, Nakagawa A, Tanaka I, Nishihira J, Sakai M. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol (1996) 3(3):259-66. doi:10.1038/nsb0396-259
9. Al-Abed Y, VanPatten S. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem (2011) 3(1):45-63. doi:10.4155/fmc.10.281
10. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med (2001) 27(8):1412-5. doi:10.1007/s001340101022
11. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 42(8):1601-8.
12. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol (2004) 31(2):268-73.
13. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation (2008) 117(12):1594-602. doi:10.1161/CIRCULATIONAHA.107.729125
14. Burger-Kentischer A, Göbel H, Kleemann R, Zernecke A, Bucala R, Leng L, et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis (2006) 184(1):28-38. doi:10.1016/j.atherosclerosis.2005.03.028
15. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation (2004) 109(3):380-5. doi:10.1161/01.CIR.0000109201.72441.09
16. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int (2005) 67(4):1216-33. doi:10.1111/j.1523-1755.2005.00200.x
17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 351(13):1296-305. doi:10.1056/NEJMoa041031
18. Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol (2002) 13(Suppl 1):S7-13.
19. Hong MY, Tseng CC, Chuang CC, Chen CL, Lin SH, Lin CF. Urinary macrophage migration inhibitory factor serves as a potential biomarker for acute kidney injury in patients with acute pyelonephritis. Mediators Inflamm (2012) 2012:381358. doi:10.1155/2012/381358
20. Brown FG, Nikolic-Paterson DJ, Chadban SJ, Dowling J, Jose M, Metz CN, et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation (2001) 71:1777-83. doi:10.1097/00007890-200106270-00013
21. Payen D, Lukaszewicz AC, Legrand M, Gayat E, Faivre V, Megarbane B, et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. PLoS One (2012) 7:e35838. doi:10.1371/journal.pone.0035838
22. Takahashi K, Koga K, Linge HM, Zhang Y, Lin X, Metz CN, et al. Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res (2009) 10:33. doi:10.1186/1465-9921-10-33
23. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol (2003) 199:496-508. doi:10.1002/path.1291
24. Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 185:1455-65. doi:10.1084/jem.185.8.1455
25. Stefaniak J, Schiefer J, Miller EJ, Krenn CG, Baron DM, Faybik P. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation. Liver Transpl (2015) 21(5):662-9. doi:10.1002/lt.24103
26. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int (2015) 88(5):950-7. doi:10.1038/ki.2015.230
27. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the kidney early evaluation program (KEEP). Am J Kidney Dis (2010) 55(3 Suppl 2):S23-33. doi:10.1053/j.ajkd.2009.09.035
28. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med (2010) 268:456-67. doi:10.1111/j.1365-2796.2010.02269.x
29. Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. Chronic kidney disease and premature ageing. Nat Rev Nephrol (2014) 10:732-42. doi:10.1038/nrneph.2014.185
30. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (1998) 32(5 Suppl 3):S112-9. doi:10.1053/ajkd.1998.v32.pm9820470
31. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis (2013) 62:339-51. doi:10.1053/j.ajkd.2012.11.051
32. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 47:139-48. doi:10.1053/j.ajkd.2005.09.014
33. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant (2011) 26:1313-8. doi:10.1093/ndt/gfq557
34. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med (2008) 14:109-15. doi:10.2119/2007-00107.Bruchfeld
35. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol (2012) 7:1938-46. doi:10.2215/CJN.03500412
36. Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimburger O, et al. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med (2009) 15(3-4):70-5. doi:10.2119/molmed.2008.00109
37. Rammos C, Hendgen-Cotta UB, Sobierajski J, Adamczyk S, Hetzel GR, Kleophas W, et al. Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease. Int J Cardiol (2013) 168(6):5249-56. doi:10.1016/j.ijcard.2013.08.021
38. Haddad F, Fuh E, Peterson T, Skhiri M, Kudelko KT, De Jesus Perez V, et al. Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail (2011) 17(7):533-9. doi:10.1016/j.cardfail.2011.03.003
39. Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation (2008) 117(19):2475-83. doi:10.1161/CIRCULATIONAHA.107.719500
40. Zhang B, Luo Y, Liu ML, Wang J, Xu DQ, Dong MQ, et al. Macrophage migration inhibitory factor contributes to hypoxic pulmonary vasoconstriction in rats. Microvasc Res (2012) 83(2):205-12. doi:10.1016/j.mvr.2011.09.014
41. Thomas L. Petty Aspen Lung Conference 55th Annual Meeting: Aspen. Colorado (2012). p. 6-9.
42. Ahmed MN, Zhang Y, Codipilly C, Zaghloul N, Patel D, Wolin M, et al. Extracellular superoxide dismutase overexpression can reverse the course of hypoxia-induced pulmonary hypertension. Mol Med (2012) 18(1):38-46. doi:10.2119/molmed.2011.00339
43. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol (2013) 24(2):302-8. doi:10.1681/ASN.2012070718
44. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol (2005) 16(6):1537-8. doi:10.1681/ASN.2005040393
45. Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep (2006) 6(6):463-8. doi:10.1007/s11892-006-0080-1
46. Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the cooperative health research in the region of Augsburg, Survey 4 (KORA S4). Diabetes Care (2006) 29(2):368-71. doi:10.2337/diacare.29.02.06.dc05-1474
47. Makino A, Nakamura T, Hirano M, Kitta Y, Sano K, Kobayashi T, et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis (2010) 213(2):573-8. doi:10.1016/j.atherosclerosis.2010.09.004
48. Schöttker B, Herder C, Rothenbacher D, Roden M, Kolb H, Müller H, et al. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care (2013) 36(6):1703-11. doi:10.2337/dc12-1416
49. Watanabe T, Tomioka NH, Doshi M, Watanabe S, Tsuchiya M, Hosoyamada M. Macrophage migration inhibitory factor is a possible candidate for the induction of microalbuminuria in diabetic db/db mice. Biol Pharm Bull (2013) 36(5):741-7. doi:10.1248/bpb.b12-00741
50. Sanchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol (2009) 20(2):353-62. doi:10.1681/ASN.2008020194
51. Wang Z, Wei M, Wang M, Chen L, Liu H, Ren Y, et al. Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice. Inflammation (2014) 37(6):2020-9. doi:10.1007/s10753-014-9934-x
52. Lan HY, Mu W, Yang N, Meinhardt A, Nikolic-Paterson DJ, Ng YY, et al. De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol (1996) 149(4):1119-27.
53. Yang N, Nikolic-Paterson DJ, Ng YY, Mu W, Metz C, Bacher M, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med (1998) 4(6):413-24.
54. Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int (2000) 57(2):499-509. doi:10.1046/j.1523-1755.2000.00869.x
55. Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol (2008) 28(1):4-9. doi:10.1016/j.semnephrol.2007.10.001
56. Matsumoto K, Kanmatsuse K. Increased production of macrophage migration inhibitory factor by T cells in patients with IgA nephropathy. Am J Nephrol (2001) 21(6):455-64. doi:10.1159/000046649
57. Leung JC, Tang SC, Chan LY, Tsang AW, Lan HY, Lai KN. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant (2003) 18(1):36-45. doi:10.1093/ndt/18.1.36
58. Leung JC, Chan LY, Tsang AW, Liu EW, Lam MF, Tang SC, et al. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrol Dial Transplant (2004) 19(8):1976-85. doi:10.1093/ndt/gfh323
59. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol (2014) 10(8):463-73. doi:10.1038/nrrheum.2014.103
60. Becker H, Maaser C, Mickholz E, Dyong A, Domschke W, Gaubitz M. Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol (2006) 25(3):368-72. doi:10.1007/s10067-005-0045-9
61. Wendt M, Börjesson O, Avik A, Bratt J, Anderstam B, Qureshi AR, et al. Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Mol Med (2013) 19:109-14. doi:10.2119/molmed.2012.00352
62. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 377(6544):68-71. doi:10.1038/377068a0
63. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, et al. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 22(12):3508-15. doi:10.1093/ndt/gfm493
64. Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term follow-up study. Arthritis Rheum (2005) 53(1):108-13. doi:10.1002/art.20927
65. Al-Abed Y, Metz CN, Cheng KF, Aljabari B, VanPatten S, Blau S. Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proc Natl Acad Sci U S A (2011) 108(20):8224-7. doi:10.1073/pnas.1017624108
66. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol (2013) 24(6):1006-13. doi:10.1681/ASN.2012070650
67. Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, et al. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest (2015) 125(6):2399-412. doi:10.1172/JCI80467
68. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 367(25):2407-18. doi:10.1056/NEJMoa1205511
69. Renner P, Roger T, Calandra T. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis (2005) 41:513-9. doi:10.1086/432009
70. Gao L, Flores C, Fan-Ma S, Miller EJ, Moitra J, Moreno L, et al. Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. Transl Res (2007) 150(1):18-29. doi:10.1016/j.trsl.2007.02.007
71. Tripathi G, Borkar M, Akhter A, Sankhwar SN, Sharma RK, Agrawal S. Association of proinflammatory cytokines with end stage renal disease. Cytokine (2010) 50(3):278-83. doi:10.1016/j.cyto.2010.02.019
72. Vivarelli M, D'Urbano LE, Stringini G, Ghiggeri GM, Caridi G, Donn R, et al. Association of the macrophage migration inhibitory factor-173*C allele with childhood nephrotic syndrome. Pediatr Nephrol (2008) 23(5):743-8. doi:10.1007/s00467-007-0729-2
73. Sreih AG, Ezzeddine R, Fan J, Leng L, Carette S, Cuthbertson D, et al. The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis. Abstract. Boston: American College of Rheumatology (2014).
74. Koga K, Kenessey A, Powell SR, Sison CP, Miller EJ, Ojamaa K. Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid Redox Signal (2011) 14(7):1191-202. doi:10.1089/ars.2010.3163
75. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature (2008) 451(7178):578-82. doi:10.1038/nature06504
76. Thiele M, Kerschbaumer RJ, Tam FW, Völkel D, Douillard P, Schinagl A, et al. Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions. J Immunol (2015) 195(5):2343-52. doi:10.4049/jimmunol.1500572